Evotec

Missed our live webinars on “Mastering Quality by Design”? Catch up on-demand! Evotec’s Quality by Design webinar series is now available to stream on-demand. Dive into the sessions at your convenience and gain valuable insights into QbD’s role in enhancing pharmaceutical quality. https://hubs.ly/Q02Hsm2T0. #drugdevelopment #QualityByDesign

In the quest to revolutionize immunotherapy, the identification of naturally presented peptides bound to HLA class I and II molecules from cancerous cells holds paramount importance. Evotec’s pioneering immunopeptidomics platform stands at the forefront, enabling the unbiased discovery of novel immunotherapeutic targets. Learn more about Evotec’s immunopeptidomics platform in our latest blog, Advancing Immunotherapy through Immunopeptidome Deciphering for Neoantigen Identification. https://hubs.ly/Q02H5HSv0

Evotec Machine Learning Scientist wins "Biomarker of Aging Challenge" Age-related disease is an important therapeutic area for Evotec. Our aim is slow down age-related diseases allowing people to maintain a high quality of life throughout their later decades. Understanding these natural patterns and signatures of ageing helps us identify novel targets / biomarkers plus support work with our partners. In Evotec Bioinformatics we apply machine learning algorithms to high-dimensional omics data, e.g. to predict compound toxicity or to find disease biomarkers. Hence, we got excited when the Biomarkers of Aging Consortium together with the Methuselah Foundation and the VoLo Foundation created the Biomarkers of Aging Challenge. In this challenge, scientists from many excellent research institutions across the world compete for the best models to predict chronological age, mortality, and multi-morbidity. In collaboration with disease experts from the In Vitro Biology department, ML Scientist Julian Reinhard developed a deep learning model predicting chronological age based on methylation data provided by the consortium. It was a tight race, but now the results for the first phase of the challenge are in: Julian won the 1st place with a final score of 2.45 year age error! Congratulations to Julian! https://hubs.ly/Q02HXg0c0 #researchneverstops #biomarker

David Pardoe, SVP and Head of Global Molecular Architects at Evotec, lays out the stark challenges for drug discovery, and the urgent response that AI can help to drive in a recent discussion with GT life science, "Now is the time that we DO need automation...to harvest all of that information and data - largely unstructured - to put it into a form that we can easily exploit and explore, and to help us make those really difficult in drug discovery and development." Check out the video here- https://hubs.ly/Q02H5-S10?

Curious to learn about hit identification and high throughput screening strategies at Evotec? Join our 5-part webinar series now. The first 3 episodes are already available on demand, while new episodes in September and October are open for registration now. Overview of the episodes: #1: Unlocking High Throughput Hit Identification Strategies, with Thomas Ahrens #2: It All Starts With a Protein – Protein Sciences as a Key to Success in Drug Discovery, with James Errey #3: Molecular Interactions Matter - Biophysical Screening for Early Drug Discovery, with Florian Krieger #4: The Role of Structural Insights in Drug Discovery, with Jay Bertrand #5: Illuminating Cellular Processes through High Content Methods, with Karsten Kottig and Sven Schreiter To find more information, and to get access to the individual sessions, please visit: https://hubs.ly/Q02H5HRr0 #researchneverstops #Evotec #drugdiscovery

The new ICH M12 Guideline for drug-drug interaction studies is out. Here is everything you need to learn about the latest changes and the best practices to stay compliant. Read here- https://hubs.ly/Q02HqW7c0 For further enquiries, contact us at [email protected]

As the world increasingly focuses on sustainability, the pharmaceutical and biotech industry is following suit. Evotec is not just setting the benchmark for sustainability in drug discovery; we are proving that excellence in medicinal chemistry and environmental stewardship can go hand in hand. As we continue to innovate and implement green practices, Evotec is paving the way for a more sustainable future in pharmaceuticals. Read more about Evotec’s green chemistry initiatives and their impact on the pharmaceutical industry in our latest blog post! https://hubs.ly/Q02H5RHm0 #researchneverstops #Sustainability #GreenChemistry

The third episode of our webinar series on hit identification and high throughput screening strategies is now available on demand! Episode 3: Molecular Interactions Matter - Biophysical Screening for Early Drug Discovery Dr. Florian Krieger, VP Biophysics, discusses Evotec’s most recent developments in biophysical screening approaches during early drug discovery stages. He also shares valuable insights into case studies covering lead-like screening, fragment-based approaches, and covalent hit identification. Stream the webinar now! https://hubs.ly/Q02Hd4f10 #researchneverstops #Evotec #drugdiscovery

The #CRYO2024 Meeting begins next week, featuring a podium presentation by our expert, Olga Shatnyeva, PhD. She will present within the session titled “TOWARDS ON-DEMAND TISSUES: RECENT ADVANCEMENT IN ICE-FREE BIOPRESERVATION.” Her talk entitled “Optimization of Exosome Preservation and Storage for Diagnostic and Therapeutic Applications,” will discuss how preservation and storage conditions significantly impact extracellular vesicle (EV) characteristics, including size, content, and functionality, both pre- and post-isolation. The session is scheduled for July 24 at 2:00 PM EST. For more details, view the program- https://hubs.ly/Q02HcNWj0. #Exosomes #ResearchNeverStops #CRYO2024 #EV #ExtracellularVesicles #CellTherapy

Evotec is proud to host Prof. Carlo Rinaldi, Associate Professor, University of Oxford as the first speaker of its new webinar series on Oligonucleotides Therapeutics: Discovery to Development. Prof. Rinaldi will present on: Targeting transcription factor for therapy in neuromuscular diseases. The live presentation will be followed by a Q&A session, moderated by our Principal Scientist, In vitro Pharmacology, Jacopo Oieni. Date: 23 July 2024 Time: 5:00pm CET | 4:00pm BST | 11:00am EST | 8:00am PST For all details about the webinar and to register - https://hubs.ly/Q02H52WN0